[68Ga]Ga-FAPI-46: an imaging biomarker for FAP-positive tumours
Mené sur 155 patients atteints d'un cancer (âge médian : 62 ans ; durée médiane de suivi : 29 jours ; 37 % de femmes), cet essai de phase II évalue la sécurité et la performance potentielle, pour détecter les tumeurs exprimant la protéine d'activation des fibroblastes alpha (FAP), d'une tomographie numérique par émission de positrons avec radiotraceur
[18F]FDG continues to be the main radiopharmaceutical for PET–CT scans in oncology, but there is growing evidence on new radiopharmaceuticals that can improve patient management with a special focus on precision and personalised medicine, providing higher imaging efficacy than [18F]FDG and permitting theranostic applications. Fibroblast activation protein
α inhibitor (FAPI) radiopharmaceuticals are one such example.
The target of FAPI used for PET–CT imaging is FAP, a type II cell membrane-bound serine peptidase, which is overexpressed on the surface of cancer-associated fibroblasts. These cancer-associated fibroblasts form part of the stroma, or the tumoural microenvironment, together with other cellular subtypes. The stroma and tumour cells form the tumour mass, with the stroma accounting for up to 90% of the neoplastic mass. Remarkably, FAP is overexpressed in a high proportion of epithelial tumours, meaning that FAPI-based radiopharmaceuticals are pan-tumour markers.
The Lancet Oncology , commentaire, 2025